Sarah Walker - Concepedia

Author

Sarah Walker

Also Known As

A. Babiker, Di Gibb, S Walker, S. Walker, Sarah A Walker, Sarah A. Walker, Sarah P Walker, Sarah P. Walker, Sarah Walker, WALKER, Sarah A.

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

MRC Clinical Trials Unit at UCL University College London Medical Research Council Joint Clinical Research Centre University of Zimbabwe

About

Sarah Walker is an author at MRC Clinical Trials Unit at UCL specializing in medicine, health sciences, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	255
2	Health Sciences	4	4	344
3	Engineering	1	1	17
4	Public Health	1	1	179
5	Clinical Nutrition	1	1	179

Sarah Walker

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy Benôıt Marin, Rodolphe Thiébaut, Heiner C. Bucher, AIDS	2009	222
Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: Evaluation of various criteria used to identify malnutrition HuiChuan J. Lai, Michael R. Kosorok, Sherie A. Sondel, The Journal of Pediatrics MalnutritionNutritionBody CompositionChild HealthClinical Nutrition	1998	179
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, The Lancet HIV	2022	131
Randomization-based methods for correcting for treatment changes: examples from the Concorde trial Ian R. White, A. G. A. G. Babiker, Sarah Walker, Statistics in Medicine Randomization-based MethodsTreatment EffectPharmacotherapyTreatment ChangesEvent Times	1999	88
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial Nicholas I. Paton, Cissy Kityo, Immaculate Nankya, The Lancet HIV	2017	79
Highly Active Antiretroviral Therapy Interruption Giota Touloumi, Nikos Pantazis, Anna Antoniou, JAIDS Journal of Acquired Immune Deficiency Syndromes	2006	66
Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates Giota Touloumi, Nikos Pantazis, Abdel G. Babiker, AIDS	2004	65
Impact of Cotrimoxazole on Carriage and Antibiotic Resistance of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> in HIV-Infected Children in Zambia Darlington Mwenya, Bambos M. Charalambous, Patrick Phillips, Antimicrobial Agents and Chemotherapy Antimicrobial ChemotherapyAntibiotic ResistanceDrug ResistanceCotrimoxazole ResistanceHigh Cotrimoxazole Resistance	2010	47
Plasma Pharmacokinetics of Once- versus Twice-Daily Lamivudine and Abacavir: Simplification of Combination Treatment in HIV-1-Infected Children (Penta-13) Alina S Bergshoeff, David M. Burger, Corrien Verweij, Antiviral Therapy Hiv-1-infected ChildrenIntracellular PharmacokineticsPharmacotherapyAntiviral DrugSteady State	2005	46
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Alina S Bergshoeff, David M. Burger, Corrien Verweij, PubMed	2005	43

Page 1